{"filing":{"accession_number":"0001193125-26-335212","cik":"0001831915","ticker":"CTKB","company_name":"Cytek Biosciences, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"d118986d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/d118986d8k.htm"},"events":[{"id":24763,"run_id":22450,"accession_number":"0001193125-26-335212","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Cytek Biosciences issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $48.1 million (6% increase YoY), gross profit of $28.3 million (19% increase YoY), and updated full-year 2026 revenue guidance to $207–$212 million. This is a standard quarterly earnings release furnished under Item 2.02 and is material to investors assessing the company's financial performance and trajectory.","company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25428,"accession_number":"0001193125-26-335212","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Cytek Biosciences issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $48.1 million (6% increase YoY), gross profit of $28.3 million (19% increase YoY), and updated full-year 2026 revenue guidance to $207–$212 million. This is a standard quarterly earnings release furnished under Item 2.02 and is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:19:49.473691+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25428,"accession_number":"0001193125-26-335212","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Cytek Biosciences issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $48.1 million (6% increase YoY), gross profit of $28.3 million (19% increase YoY), and updated full-year 2026 revenue guidance to $207–$212 million. This is a standard quarterly earnings release furnished under Item 2.02 and is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:19:49.473691+00:00","company_name":"Cytek Biosciences, Inc.","ticker":"CTKB","filing_date":"2026-08-05"}]}